---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-241968"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:24:25.192634+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics appoints Katina Dorton to board; Mardi Dier resigns

## Summary
- Mardi Dier resigned as Class III director effective Oct 17, 2025, not due to any disagreement.
- Katina Dorton, J.D., MBA, appointed as Class III director and Audit Committee Chair, effective Oct 17.
- Dorton brings 30+ years of healthcare finance and board experience; served as CFO at NodThera.
- Dorton received option to purchase 76,000 shares vesting over 3 years under 2020 Equity Incentive Plan.
- Dorton also serves on boards of Fulcrum Therapeutics (FULC) and TScan Therapeutics (TCRX).

## SEC filing metadata
- accession: 0001193125-25-241968
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312525241968/0001193125-25-241968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312525241968/prld-20251015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-241968
- JSON: https://secwatch.observer/filing/0001193125-25-241968.json
- Plain text: https://secwatch.observer/filing/0001193125-25-241968.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.